Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know

Group 1 - Monopar Therapeutics Inc. (MNPR) closed at $34.51, with a 2% gain over the past four weeks, and a mean price target of $52.20 indicating a 51.3% upside potential [1] - The average price targets range from a low of $37 to a high of $76, with a standard deviation of $15.69, suggesting variability in analyst estimates [2] - Analysts show strong agreement on MNPR's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 15.2% over the past month, with two estimates going higher and no negative revisions [12] - MNPR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate potential price movement direction [10][13]